[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"septic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:septic-arthritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,72,99,130,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100626792","phase-2-evaluation-of-the-efficacy-of-corticosteroids-in-septic-arthritis-in-adults-100626792",false,"NCT07440238","Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults","Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults: Randomized Double-blind Controlled Trial","CORSAR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Documented septic arthritis (microorganism identified intra-articularly by culture or PCR, or by turbid synovial fluid with positive Gram stain, or positive blood cultures)\n* Effective antibiotic therapy initiated within ≤ 3 days\n* Effective contraception for women of childbearing age during treatment period\n* Signed informed consent\n* Affiliation to the French national health insurance system\n* Ability to read, write, and understand French\n\nExclusion Criteria:\n\n* Polyarticular septic arthritis (≥ 2 joints)\n* Septic arthritis of small joints (e.g., fingers: proximal interphalangeal joint (PIP), distal interphalangeal joints (DIP), MetaCarpoPhalangeal (MCP); toes: MTP)\n* Systemic sclerosis\n* Pyomyositis\n* Diabetic foot infection\n* Current corticosteroid therapy for another indication\n* Inability to take oral medication\n* Contraindication to corticosteroids\n* Associated endocarditis\n* Presence of prosthetic joint or osteosynthesis material in the affected joint\n* Septic shock\n* Severe soft tissue wound overlying the joint\n* Aplastic chemotherapy\n* Neutropenia (defined as neutrophils \\\u003C 500\u002Fmm³)\n* Mycobacterial infection\n* Fungal infection\n* Sickle cell disease\n* Current pregnancy\n* Breastfeeding women\n* Patients under legal protection (e.g., guardianship)\n* Participation in another interventional clinical trial\n* Uncontrolled diabetes\n* Unstable psychiatric disorders\n* Adults unable to provide informed consent\n* Contraindication to corticosteroid therapy","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Septic arthritis is a severe infection associated with significant morbidity and mortality. Despite eradication of the microorganisms, persistent inflammation may lead to substantial long-term functional joint sequelae. The use of corticosteroids could reduce this inflammation, thereby improving functional joint outcomes and facilitating first-line medical treatment. The hypothesis of this study is that corticosteroid administration, in addition to antibiotic therapy, reduces persistent inflammation and improves functional joint prognosis in adult patients with acute septic arthritis.",[27],"Septic Arthritis",[29,30,31,32],"Articular prognosis","Corticosteroid","Acute septic arthritis","Antibiotic therapy","NOT_YET_RECRUITING","2026-02-26",{"date":36,"type":37},"2026-02-27","ACTUAL",{"date":39,"type":21},"2026-03-30",{"date":41,"type":21},"2026-09",{"name":43,"class":44},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100622776","infrared-thermography-for-diagnosis-of-musculoskeletal-infections-100622776","NCT07388017","Infrared Thermography for Diagnosis of Musculoskeletal Infections","High Resolution Thermographic Imaging as a Diagnostic Aid in Paediatric Infections of Bones, Joints, and Soft Tissues","Inclusion Criteria:\n\n* Children and young people from neonates to 15 years of age:\n* With clinical suspicion of a primary MSK infection (irrespective of location or aetiology), as defined by presenting symptoms, physical examination and bloodwork performed by a qualified clinician.\n* Presenting to Sheffield Children's Hospital via A\\&E or referral from another hospital.\n* Who are able to interpret the information given in the information sheet\u002Fassent form on paper in English (with the exception of children under the age of 3 years who are not required to assent.)\n* With at least 1 competent legal guardian who is capable of legally consenting, and interpreting the information given in the information sheet in English.\n* Where a medical doctor involved in their care has agreed that their participation in the study will not negatively impact on their treatment outcome\n\nExclusion Criteria:\n\n* \\- Have a secondary MSK infection.\n* Are severely ill or need urgent\u002Fcritical attention or have comorbid conditions that will complicate their care, as decided by a medical doctor involved in their treatment.\n* Patients with conditions including but not limited to leukaemia, hyper\u002Fhypothyroidism, diabetes mellitus or any other condition that affects their basal metabolic rate\u002Fbody temperature.\n* Amputees where the amputated region is contralateral to the region of suspected infection.\n* Have received an a priori diagnosis or have already undergone any investigation. This includes patients admitted for a recurrence\u002Fexacerbation of recently diagnosed MSK infection.\n* Any patient where the medical team responsible for their treatment raises concerns that HRTI could negatively impact their treatment outcome.\n* The patient, or their legal guardian(s) do not consent or assent\u002Fwithdraw consent or assent\u002F or are not able to consent or assent for any reason. (Eg. The patient\u002Fguardian(s) are non-English speakers or have disabilities impairing their understanding of the study.)","0 Years","15 Years",{"count":56,"type":21},30,"OBSERVATIONAL","This is a pilot proof of feasibility study to explore the efficacy of High Resolution Infrared Thermographic Imaging (HRTI) to assist with the detection of musculoskeletal infections in children. In HRTI, a sensitive thermal camera is used to capture the temperature profile of the suspected infected body region in the form of images. In this study, a 10-second video will be recorded to allow dynamic monitoring. The resulting video will be processed and interpreted to determine whether there is a musculoskeletal infection.\n\nBone, joint and soft tissue infections can be caused by bacteria which can enter the body through accidental injuries, or because of surgery or implants. Once in the body, they circulate through the bloodstream until they reach a bone, joint, or muscle, multiply and cause infection. These conditions can cause significant complications in children and adults and can even result in death if untreated.\n\nInfections of the bone, called osteomyelitis can inhibit bone growth in children. As a result, children who have suffered from osteomyelitis may require extensive treatment later in childhood. While osteomyelitis accounts for only 1% of childhood hospital admissions, its incidence in children has increased in recent decades. This is associated with an increase in the prevalence of antibiotic resistant bacteria such as MRSA.\n\nInfections of the joint, called septic arthritis, is an emergency condition that requires prompt diagnosis and treatment. Long delays in diagnosis and surgical drainage of the joint may lead to irreversible damage to the cartilage and bone destruction.\n\nThere is currently a need for improved technologies to screen for and monitor bone, joint, and soft tissue infections. Plain radiographs appear normal in the first 7 to 10 days of osteomyelitis. Magnetic resonance imaging (MRI) is the most sensitive modality for diagnosing osteomyelitis. However, MRI scans are costly their accessibility is limited, plus the scan can take 30 minutes to perform. As the child needs to be still during the scan, sedation is required.\n\nInfrared thermal imaging is a harmless, cost effective and rapid scanning method that has proven industrial applications such as condition monitoring of machineries and fault findings. There has also been extensive interest in utilising and this technology for medical diagnosis and monitoring. This study builds on our earlier work that used HRTI to detect inflammation in the abdomen in infants. This technology may allow timelier and more cost-effective diagnosis of the condition. Sheffield Children's Hospital and Sheffield Hallam University collaborate in conducting the study.\n\nThe study will involve recruiting 30 patients at Sheffield Children's Hospital with suspected infection of either bone, joint or soft tissue. They will have their HRTI recorded and processed to follow up the study's research questions. The findings from the study will not alter the routine medical treatments of the patients and participation is voluntary.",[60,27,61],"Musculoskeletal Infection","Osteomyelitis\u002FSeptic Arthritis","RECRUITING","2026-01-27",{"date":65,"type":37},"2026-02-04",{"date":67,"type":37},"2025-02-17",{"date":69,"type":21},"2026-01-31",{"name":71,"class":44},"Sheffield Children's NHS Foundation Trust",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100403801","phase-4-bone-and-joint-infections---simplifying-treatment-in-children-trial-100403801","NCT04538053","BonE and Joint Infections - Simplifying Treatment in Children Trial","BEST","Inclusion Criteria:\n\n* Children aged 1 to 18 years with acute, uncomplicated, community-acquired bone and joint infection who fulfil pre-defined clinical criteria.\n\nExclusion Criteria:\n\n1. Infection due to bacteria resistant to cefalexin or atypical infection (e.g. mycobacterial, fungal)\n2. Features of sepsis as defined by the presence of organ dysfunction (defined using definitions within the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score)\n3. Concomitant severe, invasive infection e.g. necrosing fasciitis\n4. Complicated infection (e.g. presence of prosthetic material; large subperiosteal (\\>3mm) or soft tissue abscess without surgical intervention; infection secondary to or complicated by trauma)\n5. History of allergy to cephalosporin antibiotics or immediate, severe reaction to penicillins\n6. Received more than three IV or oral dose of an antibiotic with activity against the likely bacteria causing the current infection\n7. Prior episode of OM or SA\n8. Prior condition predisposing to poor absorption (e.g. inflammatory bowel disease, current gastrointestinal symptoms) or complicated disease (e.g. immunodeficiency)\n9. Prior enrolment in the trial\n10. Current recipient of another investigational product as part of a clinical trial","1 Year",{"count":81,"type":21},285,[83],"PHASE4","This is a multi- centre trial of children with bone and joint infections (BJIs) at eight major paediatric hospitals in Australia and New Zealand. The primary objective is to establish if in children with acute, uncomplicated BJIs, entirely oral antibiotic treatment is not inferior to initial intravenous (IV) treatment for 1 to 7 days followed by an oral antibiotic course in achieving full recovery 3 months after presentation. Children will be randomly allocated to the 'entirely oral antibiotic' group or the 'standard treatment' group.",[86,27,87,88],"Bone Infection","Bone and Joint Infection","Osteomyelitis","2025-11-14",{"date":91,"type":37},"2025-11-17",{"date":93,"type":37},"2021-06-01",{"date":95,"type":21},"2026-12",{"name":97,"class":44},"Murdoch Childrens Research Institute",10,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100339842","alpha-defensin-and-synovial-proteins-to-improve-detection-of-pediatric-septic-arthritis-100339842","NCT03704766","Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis","Inclusion Criteria- Septic Cases and Inflamed, Non-Septic Comparators:\n\n* Synovial fluid is obtained to assess for infection or inflammatory\u002Frheumatologic disease (all medium and large joints will be included: hip, knee, ankle, shoulder, subtalar, elbow, and wrist joints)\n* Patients with recent antibiotic exposure are eligible to participate but will be analyzed separately\n\nInclusion Criteria- Normative Controls:\n\n* Patients undergoing a procedure unrelated to infection (the procedure may be arthroscopy, or an open or percutaneous bony or soft tissue procedure)\n\nExclusion Criteria- All Participants:\n\n* Family declines to participate\u002Fconsent\n* Patients with a major joint trauma (such as a documented ligament tear or fracture) within the past 8 weeks are not eligible to have that joint aspirated, but could have another joint aspirated\n\nExclusion Criteria- Normative Controls:\n\n* A history of recent infection (within the past 3 months)\n* Received antibiotics in the past 7 days","17 Years",{"count":107,"type":21},442,[109],"NA","Differentiating between septic arthritis and other causes of joint inflammation in pediatric patients is challenging and of the utmost importance because septic arthritis requires surgical debridement as part of the treatment regimen. The current gold standard to diagnose septic arthritis in children is a positive synovial fluid culture; however, joint cultures may take several days to return. If a bacterial infection is present, it requires immediate surgical intervention in order to prevent lasting articular cartilage damage. Frequently surgeons must decide whether to surgically debride a joint before culture results are available. There is no single lab test or clinical feature that reliably indicates bacterial infection over other causes of joint inflammation. The alpha-defensin assay has shown high sensitivity and specificity for joint infection in other studies.The purpose of this study is to determine the sensitivity and specificity of several synovial biomarkers for diagnosing pediatric septic arthritis.",[112,113,114,27],"Joint Infection","Infection of Hip Joint (Disorder)","Infection of Shoulder Joint",[116,117,118,119],"synovial biomarkers","alpha-defensin","diagnostics","pediatric","2025-06-17",{"date":122,"type":37},"2025-06-22",{"date":124,"type":37},"2016-06-28",{"date":126,"type":21},"2026-05",{"name":128,"class":44},"Hospital for Special Surgery, New York",3,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":137,"maxAge":18,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":151,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":45},"100591567","phase-4-trimethoprim-sulfamethoxazole-vs-clindamycin-for-the-treatment-of-children-with-invasive-mrsa-infections-100591567","NCT06982105","Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections","Comparing Optimal Step-down Therapy for Children With Invasive MRSA Trimethoprim-Sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections","Inclusion Criteria:\n\n1. 60 days to 18 years of age (inclusive) at the time of oral step down treatment\n2. Diagnosed by the clinical team with OAI or HNI:\n\n   * OAI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of OAI\n\n     * Focal finding- pain\u002Fswelling over a bone\u002Fjoint, or restricted movement\u002Ffailure to bear weight\n     * Systemic finding- fever \\>38oC, or elevated c-reactive protein (CRP) or elevated erythrocyte sedimentation rate. (ESR) or elevated white blood cell count (WBC) or elevated WBC in synovial fluid OR\n     * Radiographic confirmation- findings consistent with osteomyelitis or septic arthritis - Plain radiograph, MRI, CT or ultrasound, bone scan result indicating abnormal bone, subperiosteal or bone marrow findings consistent with infection\n   * HNI- at least 1 focal finding and 1 systemic finding OR radiographic confirmation of HNI\n\n     * Focal finding- facial pain or redness, eye pain or proptosis, neck or throat pain or swelling, ear pain or proptosis\n     * Systemic finding- fever \\>38oC, or elevated CRP or elevated ESR or elevated WBC OR\n     * Radiographic confirmation- findings consistent with facial\u002Forbital cellulitis, cervical lymphadenitis, mastoiditis, or deep neck infection\u002Fabscess (including peritonsillar, retro- and para-pharyngeal. Plain radiograph, MRI, CT or ultrasound, bone scan result indicating abnormal findings consistent with infection\n3. Treated by the clinical team for confirmed MRSA or suspected MRSA infection\n\n   * Confirmed MRSA- positive culture for MRSA from a sterile body fluid (e.g., blood, abscess, bone, synovial fluid, or other surgical specimen)\n   * Suspected MRSA- treatment for MRSA by the clinical team without microbiologic confirmation (e.g., negative cultures)\n4. Currently ready or planned to be transitioned to oral antibiotic therapy by the clinical team\n5. OAI or HNI symptoms \\\u003C 14 days at the time of hospital admission\n\nExclusion Criteria:\n\n1. Enrollment in another interventional study or receipt of investigational drug as part of a research trial within the past 30 days.\n2. Known cancer, acquired or primary (including sickle cell anemia or G6PD deficiency) immunodeficiency\n3. Underlying bone disease, presence of hardware \u002Fimplantable device in affected bone\u002Fjoint\n4. Infection (OAI or HNI) resulting from penetrating wounds, open fractures, major trauma, foreign body or post-operative infection.\n5. Spinal osteomyelitis\n6. Underlying chronic renal, gastrointestinal, liver, or heart disease that would be expected to potentially affect absorption or the metabolism of assigned drug\n7. Inability to take medicine by mouth, gastrostomy, jejunostomy or nasogastric tube\n8. Received intravenous antibiotic therapy as the treatment for OAI or HNI \\>14 days.\n9. Inability or unwilling to consent\n10. Any social or medical conditions judged by the study clinician to preclude participation because it could negatively affect the participant.\n11. Allergy to both TMP-SMX and clindamycin\n12. Known MRSA isolate resistant to both TMP-SMX and clindamycin\n13. Patient is known to be pregnant at the time of enrollment","2 Months",{"count":139,"type":21},100,[83],"The goal of this clinical trial is to learn if trimethoprim-sulfamethoxazole (TMP-SMX) works to treat invasive infections due to methicillin-resistant Staphylococcus aureus (MRSA) in children. It will also learn about the safety of TMP-SMX in the treatment of children with invasive MRSA infections. The main questions it aims to answer are:\n\n-Is TMP-SMX effective at successfully treating children with invasive infections due to MRSA? What are the side effects of TMP-SMX in children taking it for invasive infections due to MRSA?\n\nResearchers will compare TMP-SMX to a clindamycin (a commonly prescribed antibiotic for the treatment of MRSA in children) to see if TMP-SMX works better, worse or the same as clindamycin for children with invasive infections due to MRSA.\n\nParticipants will:\n\nTake TMP-SMX or clindamycin for the treatment of their invasive infection due to MRSA.\n\nWill follow up with the provider treating their invasive infection at the discretion of the treating provider.\n\nKeep a diary of their symptoms and any side effects of the medicine",[143,144,27,145,146,147,148,149,150],"Methicillin Resistant Staphylococcus Aureus","Osteomyelitis Acute","Orbital Cellulitis","Facial Cellulitis","Mastoiditis","Cervical Adenitis","Retropharyngeal Abscess","Peritonsillar Abscess",[152,88,27,153,154,155,156,119],"Methicillin Resistant Staphylococcus aureus","Osteoarticular infection","Head and Neck infection","Trimethoprim sulfamethoxazole","clindamycin","2025-06-03",{"date":159,"type":37},"2025-06-04",{"date":161,"type":37},"2025-05-20",{"date":163,"type":21},"2027-06",{"name":165,"class":44},"Indiana University",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":173,"maxAge":105,"enrollmentInfo":174,"targetDuration":175,"studyType":57,"phases":4,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100579684","initial-oral-antibiotics-for-bone-and-joint-infections-in-children-100579684","NCT06827496","Initial Oral Antibiotics for Bone and Joint Infections in Children","Initial Oral Antibiotics for Bone and Joint Infections in Children: A Prospective Nationwide Real-world Effectiveness Study in Denmark","Children and adolescents aged 3 months to 17 years with uncomplicated bone and joint infections treated with initial oral antibiotics.\n\nAccording to Danish Nationwide Guidelines (initiated in 2024), initial oral antibiotics are recommended to patients with no risk factors for complicated disease. Risk factors include for complicated disease include:\n\n1. Severe illness or sepsis\n2. Rapid symptom progression\n3. Pronounced symptoms, including severe pain\n4. Pronounced soft tissue involvement\n5. Foreign material or post-surgical infection\n6. Infection with a resistent or rare pathogen, e.g., Salmonella or MRSA\n7. Severe comorbidity, including immunodeficiency\n\nPatients who have received intravenous antibiotic therapy for less than 24 h before oral antibiotics will be included","3 Months",{"count":139,"type":21},"5 Years","Initial oral antibiotic treatment for children and adolescents with uncomplicated bone and joint infections (BJI) has been found non-inferior to initial IV antibiotics in one randomized controlled trial (RCT). The real-world effectiveness of initial oral antibiotics for children and adolescents with BJI is unclear.\n\nThis nationwide, prospective, multicenter, real-world cohort study aims to compare the effectiveness and safety of initial oral antibiotic treatment for children and adolescents with uncomplicated BJI in a real-world setting with those who received initial oral antibiotics in our RCT.",[144,27,86,112,87],[179,180,181,88],"Bone and joint infections","Children","Oral antibiotics","2025-04-05",{"date":184,"type":37},"2025-04-09",{"date":186,"type":37},"2024-11-15",{"date":188,"type":21},"2027-05",{"name":190,"class":44},"Rigshospitalet, Denmark"]